RXi Pharmaceuticals Is Still On Track With Its Sd-rxRNA Technology Despite Recent Sell-Off
January 21, 2015 at 00:18 AM EST
RXi's recent results in hypertrophic scars provides an excellent buying opportunity for long term investors.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.